Skip to content
Home/Companies/Biotech/GlycoVaxyn
GL

GlycoVaxyn

Biotech·Switzerland·Exited 2015·Held 3yr

GlycoVaxyn is a healthcare / biotech company, headquartered in Switzerland.

Entry
2012
Hold
3yr
Exit
2015
Est. EV
–

Who owns GlycoVaxyn?

GlycoVaxyn was owned by Sofinnova Partners through Sofinnova Capital VII (2012 vintage) from 2012 to 2015, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VII · 2012 · Life Sciences VC

Key facts

HQSwitzerland
SectorHealthcare / Biotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2015

More from Sofinnova Capital VII

Other portfolio companies in the same fund.

Pixium Vision
Active
MedTechFrance· 2013
Advanced Perfusion Diagnostics
Exited 2018
MedTechFrance· 2012
Ascendis Pharma
Exited 2015
BiotechDenmark· 2012
EOS
Exited 2013
BiotechItaly· 2012
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings